

***Fiscal Year 2021 Prostate Cancer Research Program (PCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Early Investigator Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-PCRP-EIRA</p>	<p>By March 31, 2022</p> <p>Postdoctoral Principal Investigators (PIs):</p> <ul style="list-style-type: none"> • Must possess a doctoral degree (or equivalent) • Have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training) 	<ul style="list-style-type: none"> • Supports research opportunities focused on prostate cancer for individuals in the early stages of their careers. • PIs must have a designated mentor who is an experienced prostate cancer researcher. • Must include a Researcher Development Plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the PI’s career development. • Must address at least one of the FY21 PCRP Overarching Challenges. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$300,000 for direct costs. • The maximum period of performance is 2 years. 	<p>Pre-Application (Letter of Intent): June 17, 2021 5:00 p.m. Eastern time (ET)</p> <p>Confidential Letters of Recommendation: July 7, 2021 5:00 p.m. ET</p> <p>Application: July 1, 2021 11:59 p.m. ET</p>
<p>Physician Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-PCRP-PRA</p>	<p>At the time of application submission, the PI must be either:</p> <ul style="list-style-type: none"> • In the last year of an accredited medical residency or medical fellowship program <p style="text-align: center;"><i>or</i></p> <ul style="list-style-type: none"> • Within 5 years of having initiated a faculty appointment (including Instructor positions) 	<ul style="list-style-type: none"> • Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research. • PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice. • PIs must have a designated mentor with an established research program in prostate cancer. • Applications are strongly encouraged to demonstrate protection of at least 40% of the PI’s time for prostate cancer research (not required to be exclusive to this award). • Must include a Researcher Development Plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the PI’s career development. • Must address at least one of the FY21 PCRP Overarching Challenges. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$750,000 for direct costs. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): June 17, 2021 5:00 p.m. ET</p> <p>Confidential Letters of Recommendation: July 7, 2021 5:00 p.m. ET</p> <p>Application: July 1, 2021 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Translational Science Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-21-PCRP-TSA</p>	<p>Independent investigators at all levels</p>	<ul style="list-style-type: none"> • Supports advanced translational research that will foster transformation of promising ideas in prostate cancer into clinical applications, ultimately providing a solution to one or more of the FY21 PCRP Overarching Challenges. • Translational research may be defined as an integration of basic science and clinical observations, including a reciprocal flow of ideas and information from bench to bedside and/or bedside to bench. • Supports a broad range of translational studies such as: <ul style="list-style-type: none"> ○ Advanced translation of results from animal studies to applications with human samples/cohorts ○ Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug application submission ○ Correlative studies that are associated with an open/ongoing or completed clinical trial, e.g., projects that utilize biospecimens from clinical trial to improve clinical management of prostate cancer and/or define new areas of research ○ Projects that develop endpoints for clinical trials • Preliminary data to support the scientific rationale and feasibility of the research approaches are required. The inclusion of additional preliminary data to support the clinical relevance of the idea is strongly encouraged. • Clinical trials are not allowed. • Each PI may submit only one application. • Partnering PI Option: Allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application. Collaborations between basic science and clinical researchers are highly encouraged. • Must address at least one of the FY21 PCRP Overarching Challenges. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$750,000 for direct costs. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): July 15, 2021 5:00 p.m. ET</p> <p>Application: July 29, 2021 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Health Disparity Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-21-PCRP-HDRA</p>	<p>Established Investigators: Independent investigators at all levels</p> <p>New Investigators: Investigators that meet the following criteria at the application submission deadline date:</p> <ul style="list-style-type: none"> • Have the freedom to pursue individual aims without formal mentorship • Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award • Have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of a terminal degree (excluding residency or family medical leave) 	<ul style="list-style-type: none"> • Supports research ideas that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality. • Proposed projects must address one of the following health disparity focus areas: (1) biological contributors, (2) environmental factors, (3) social and cultural factors, or (4) access to healthcare. • Proposed projects may include basic, translational, or clinical research, including clinical trials. • Primary emphasis will be placed on the potential impact of the proposed work. • Preliminary data are encouraged, but not required. • Each PI may submit only one application. • Must address at least one of the FY21 PCRP Overarching Challenges. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$750,000 for direct costs. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): July 15, 2021 5:00 p.m. ET</p> <p>Application: July 29, 2021 11:59 p.m. ET</p>
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-21-PCRP-IDA</p>	<p>Established Investigators: Independent investigators at all levels</p> <p>New Investigators: Investigators that meet the following criteria at the application submission deadline date:</p> <ul style="list-style-type: none"> • Have the freedom to pursue individual aims without formal mentorship • Have not previously received a PCRP Idea Development Award and/or Health Disparity Research Award • Have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of terminal degree (excluding residency or family medical leave) 	<ul style="list-style-type: none"> • Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the FY21 PCRP Overarching Challenges. • Emphasis is equally placed on Innovation and Impact. • Preliminary data are encouraged, but not required. • Clinical trials are not allowed. • Each PI may submit only one application. • Multidisciplinary projects are encouraged, and multi-institutional projects are allowed. • Must address at least one of the FY21 PCRP Overarching Challenges. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$750,000 for direct costs. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): September 2, 2021 5:00 p.m. ET</p> <p>Application: September 23, 2021 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Consortium Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-21-PCRP-CCA</p>	<p>Independent investigators with a faculty-level appointment (or equivalent)</p>	<ul style="list-style-type: none"> • Supports a consortium to facilitate the rapid execution of collaborative phase 2 or phase 1/2 clinical trials that will bring to market high-impact, novel therapeutic interventions that will significantly decrease the impact of prostate cancer. • One Coordinating Center and 10 Clinical Research Sites will be selected and will be jointly responsible for proposing, selecting, and conducting trials. • Funds may not be used for research or development of clinical protocols. • Significant emphasis is placed on the inclusion of patients from diverse populations, particularly those from high-risk, underserved, and/or military populations (as described in the FY21 PCRP Overarching Challenges) • Coordinating Center applications must identify two or more Affiliate Clinical Research Sites to be supported and managed by the Coordinating Center that should have enhanced access to patients from high-risk, underserved, and/or military populations. • Clinical Research Sites must provide plans for accruing patients from diverse patient populations. 	<p>Coordinating Center:</p> <ul style="list-style-type: none"> • Maximum funding of \$7,200,000 for direct costs (plus indirect costs), including no less than \$500,000 per year for support of two or more Affiliate Clinical Research Sites. • Maximum period of performance is 4 years. <p>Clinical Sites:</p> <ul style="list-style-type: none"> • Maximum funding of \$1,200,000 for direct costs (plus indirect costs). • Maximum period of performance is 4 years 	<p>Pre-Application (Letter of Intent): September 2, 2021 5:00 p.m. Eastern time (ET)</p> <p>Application: September 23, 2021 11:59 p.m. ET</p>
<p>Data Science Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-21-PCRP-DSA</p>	<p>Independent investigators at all levels</p>	<ul style="list-style-type: none"> • Supports research where quantitative and analytical approaches, processes, and/or systems are developed and/or used to obtain knowledge and insight from large and/or complex sets of prostate cancer data. • Applications may propose development of a new data-science-driven tool or apply an existing tool or method to gather and analyze information from large data sets with the intent of advancing prostate cancer research and patient care relative to the FY21 PCRP Overarching Challenges. • Research efforts must be built upon the logic, concepts, and methods of one or more of the following research areas as they pertain to prostate cancer: <ul style="list-style-type: none"> ○ Computational Biology ○ Bioinformatics ○ Artificial Intelligence and machine learning ○ Epidemiology ○ Analysis of -omics data 	<ul style="list-style-type: none"> • Maximum funding of \$1,000,000 for direct costs (plus indirect costs). • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): July 15, 2021 5:00 p.m. ET</p> <p>Application: July 29, 2021 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<ul style="list-style-type: none"> ○ Medical Imaging ○ Digital Pathology ○ Analysis of clinically annotated datasets ● Clinical research is allowed, but must be retrospective; prospective recruitment of human subjects and/or clinical trials are not allowed. ● Presentation of preliminary data is strongly encouraged, but not required. ● Partnering Principal Investigator (PI) Option: Allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application. Collaborations between data scientists and clinicians are highly encouraged. At least one of the submitting or partnering PIs must have expertise in prostate cancer basic and/or clinical research. 		
<p>Health Equity Research and Outcomes Improvement Consortium (HEROIC) Award</p> <p>Go to:</p> <ul style="list-style-type: none"> ● Program Announcement ● General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-21-PCRP-HEROICA</p>	<p>Phase 1:</p> <p>Independent investigators with a faculty-level appointment (or equivalent)</p> <p>Phase 2:</p> <p>Independent investigators with a faculty-level appointment (or equivalent) that have previously received a phase 1 PCRP HEROIC Award</p>	<ul style="list-style-type: none"> ● Supports synergistic, multi-institutional collaborations incorporating innovative and translational approaches that have the potential to make a major impact on one or both of the following FY21 PCRP Overarching Challenges: <ul style="list-style-type: none"> ○ Advance health equity and reduce disparities in prostate cancer ○ Improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer ● Each application must outline and identify all key members of the consortium, which must include four to six Research Teams total; one Research Team will be led by a Consortium Director, and the remaining three to five Research Teams will be led by Research Team PIs. A minimum of three institutions must be represented. <ul style="list-style-type: none"> ○ Scientists and/or clinicians who have specific expertise related to health disparities or survivorship research or other areas of expertise related to addressing the overarching theme of the proposal must be included. ○ At least one prostate cancer consumer advocate must be included; the consumer advocate(s) must have an active role in every aspect of the proposed consortium’s work. ○ Teams are encouraged to also include promising Early-Career Investigators, scientists from nontraditional disciplines, and/or Epidemiologists/Public Health Experts, where appropriate. 	<p>Phase 1:</p> <ul style="list-style-type: none"> ● Maximum funding of \$2,700,000 for direct costs (plus indirect costs). ● Maximum period of performance is 2 years. <p>Phase 2:</p> <ul style="list-style-type: none"> ● Maximum funding of \$10,000,000 for direct costs (plus indirect costs). ● Maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent):</p> <p>July 15, 2021 5:00 p.m. ET</p> <p>Application:</p> <p>July 29, 2021 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<ul style="list-style-type: none"> • Consortia funding will be offered in two phases. Phase 1 awardees will be eligible to compete for phase 2 funding in FY23, pending availability of funds. <p><u>Phase 1 Funding Level</u></p> <ul style="list-style-type: none"> • Provides initial support necessary to establish the infrastructure of the consortium and conduct pilot projects. • Proposed pilot projects are intended to demonstrate proof of concept and provide preliminary data that will demonstrate the feasibility of achieving the aims that are planned for phase 2 funding. • Preliminary data may be included, but is not required. • Clinical trials are not allowed. <p><u>Phase 2 Funding Level</u></p> <ul style="list-style-type: none"> • Only recipients of a phase 1 HEROIC Award will be eligible for phase 2 funding support. It is the program’s intent that all phase 1 recipients will receive phase 2 funding pending successful achievement of phase 1 goals. • Phase 2 HEROIC Awards are expected to support research efforts including multiple, parallel projects that will build off of the preliminary data generated by the pilot projects from phase 1 and have the potential to make a major impact on advancing health equities, reducing disparities, and/or improving quality of life and overall health and wellness for those impacted by prostate cancer. • Proposed research efforts in phase 2 should emphasize translational research approaches spanning preclinical to clinical studies, with a focus on efforts that will readily translate to direct patient benefit. 		